All News

Novel approach to ank spond. Case report. #YearinReview #ACR23 @RheumNow https://t.co/fWb1qdEcOS

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Very cool targeted T cell ab treatment against TRBV9+ T cells provided remission in ankylosing spondylitis! Albeit only case report However Phase 2 ongoing @RheumNow #ACR23 https://t.co/pm64QeTo1U
Robert B Chao, MD  ( View Tweet)
Brilliant summary slide re:RA and PsA during an as-always entertaiing by Dr. Seo Personal opinion? -Persolimab will have narrow role & may cause CA -BIME will be 2nd line for PsA -Tyk-2's will be the next big thing Also... time for H2H trials!!! @RheumNow #ACR23 https://t.co/lDvsK8h7WH
Mike Putman EBRheum ( View Tweet)
#ACR23 YiR! Dr. P. Seo reviews 2023 novel therapeutic agents we may see on the horizon. @RheumNow https://t.co/d0V41jAh3G
Dr. Rachel Tate  ( View Tweet)
Considering a career in Rheumatology? Dr. Philip Seo shares latest data from Lancet Rheumatology on the burden of disease of MSK disorders 👉123%⬆️since 1990 👉⬆️by 50% in 2050! Year in Review #ACR23 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr https://t.co/iypUn9MTu6
sheila  ( View Tweet)
Can colchine reduce need for knee/hip replacement? Dr Seo #YearReview #ACR23 @RheumNow https://t.co/EpMl2nDZQ6

Links:

TheDaoIndex KDAO2011 ( View Tweet)
NORD-STAR study RA pts treated with MTX + certolizumab, abatacept, tocilizumab or triple therapy Certolizumab and Abatacept share 1st place! Toci 2nd Should we place abatacept higher on the RA tx hierarchy? @RheumNow #ACR23 https://t.co/QvyzkLOcmX
Robert B Chao, MD  ( View Tweet)
Still disgesting NORD-STAR, kind of surprised by the TCZ response? As per usual, ABA is probably an under-used option for RA @RheumNow #ACR23 https://t.co/QKyeuhqnXB
Mike Putman EBRheum ( View Tweet)
Novel therapeutics for #inflammatoryArthritis #YearInReciew #ACR23 @RheumNow https://t.co/9flVkGRn8v

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Novel therapeutics for #SLE and #SSc #ACR23 @RheumNow https://t.co/yBSaTpNZLN

Links:

TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 I’ll be at the Poster Hall tomorrow 12/11/23 between 9-11 am to present our work on clinical and biomarkers to exclude imminent autoimmune connective tissue disease #lupus #sjogren in people with ANA+. Do come and say hi 👋🏼 😃 https://t.co/wzRB7QXZsF
Md Yuzaiful Md Yusof  ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin 1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations. 2. Autoantibodies… https://t.co/TmrPqLJYzD https://t.co/ajHDVpUbhO
Paul Sufka, MD psufka ( View Tweet)
Axial PsA or AS? #ACR23 Abs #0492 finds age > 45 at LBP onset, female sex, higher frequency of PsO, and shorter time to dx may be better predictors of axial PsA. https://t.co/3sEj8NxtzP @rheumnow https://t.co/nV7NHk7WtD
Dr. Rachel Tate  ( View Tweet)
Deucravacitinib tx found to have comparable effects on PsA disease activity and PROs after 16 weeks in both male and female patients. #ACR23 Abs 0485 https://t.co/w36rX3B77K @rheumnow https://t.co/q41ioJDMML
Dr. Rachel Tate  ( View Tweet)
Racial/ethnic minority PsA pts less likely to be diagnosed w/in 12 mos from symptom onset (50% vs 71%; P < 0.001) and more frequently uninsured (8% vs. 1%; P < 0.001) compared to white pts. #ACR23 Abs #0490 https://t.co/MKO9hblGYT @rheumnow https://t.co/K8GgkhHOqw
Dr. Rachel Tate  ( View Tweet)
In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4
Dr. Rachel Tate  ( View Tweet)
Large Chicago study Abs #0535 at #ACR23 biologic tx prescribed more often for males, Non-Hispanic Blacks and Latinx in AS. Low SES, measured by SDI, and insurance status did not affect if pt received bDMARD. https://t.co/MdDuNPMCC9 @rheumnow https://t.co/Oa9aC3rbb0
Dr. Rachel Tate  ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Following on from the #ACR23 keynote, a deeper dive on how AI might actually help clinical rheumatologists in real life, from clinical rheumatologist @DrCMcMaster @DT4Health et al in @ACR_Journals: https://t.co/dQJzTwScy0 @RheumNow

David Liew drdavidliew ( View Tweet)

#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu
Dr. Rachel Tate  ( View Tweet)
×